Folate-modified hydroxyapatite nanorods induce apoptosis in MCF-7 cells through a mitochondrial-dependent pathway. (2nd September 2019)

• Record Type: Journal Article
• Authors: Wang, Huiping; He, Libang; Zhang, Peng; Zhang, Jie; Chen, Zhenhua; Ren, Xiuli; Mei, Xifan
• Is Part Of: New journal of chemistry. Volume 43:Number 37(2019)
• Page Start: 14728
• Page End: 14738
• Publication Date: 2019-09-02
• Subjects: Chemistry -- Periodicals; Chimie -- Périodiques; 540
• DOI: 10.1039/c9nj03653a
• Languages: English
• ISSNs: 1144-0546

Abstract

Abstract : The targeted delivery of therapeutic drugs into cancer cells is a facile method to improve therapeutic efficacy. Abstract : The targeted delivery of therapeutic drugs into cancer cells is a facile method to improve therapeutic efficacy. Focusing on this point, doxorubicin (DOX)-loaded hydroxyapatite (HAP) nanorods with folic acid (FA) modification (DOX@HAP-FA) have been developed for efficient antitumor treatment. In this study, DOX@HAP-FA exhibited satisfactory drug loading efficiency and significantly reduced the viability of the MCF-7 cells. Western blot assays demonstrated that DOX@HAP-FA could increase the expression of Bax (a pro-apoptotic protein) and decrease the expression of Bcl-2 (an anti-apoptotic protein). Furthermore, DOX@HAP-FA could markedly enhance mitochondrial cytochrome C leakage and thereby activate an apoptotic cascade associated with it. Thus, the designed DOX@HAP-FA nanorods showed promising potentials for targeted drug delivery in cancer therapy.